Importantly, obesity is not only involved in sustaining a low-grade inflammation through the production of cytokines such as TNF-α and IL-6, which may contribute to the increased severity of psoriasis and PsA symptoms, but may also modify the effect of therapies, especially of TNF-α inhibitors [7,8]. Here, TNF is linked to obesity due to melanocortin 4 receptor deficiency.